Myeloma / Plasma Cell Dyscrasia ~ #ASH22Top10 (or so) #mmsm #mmMRD #ASH22 - Mike Thompson, MD, PhD, FASCO *DRAFT* Table Update: Dec 10, 2022 v2 cc Surviving Myeloma & Mohamad Mohty Vincent Rajkumar + @MyelomaTeacher - Cindy Chmielewski .

After 5 Years of No CR MRD with Cilta-Cel, No Maintenance Required cancernetwork.com/view/after-5-y… via @CancerNetwork® Dr.Jagannath reports that 12 out of 37 multi-treated patients, free of disease after 5 years, should be called "cured".

Do you #knowmyeloma ? We do! Living with #myeloma for 25 years and grateful for each day together! ⁦International Myeloma Foundation⁩ ⁦Michael Tuohy⁩

Lynozyfic Approved for Relapsed/Refractory Multiple Myeloma hematologyadvisor.com/news/lynozyfic…

What cure looks like. #IMS25 This is what we should aspire for and define as cure in myeloma and other cancers. 1/

The innovators often see the future when the mainstream are blind to the possibility! Dr. Kyle and Dr. Barlogie were visionaries!

So true, but so misunderstood!

If your insurance company says no: APPEAL! It works 40-60% of the time! ⁦International Myeloma Foundation⁩ #mmsm #myeloma ⁦Joseph Mikhael⁩ ⁦Jenn Wieworka⁩ ⁦Triage Cancer⁩

How I manage MGUS in one Figure 👇

I am scared of using CART or bispecifics in myeloma with large volume disease: CRS, neurotoxicity, HLH, risk of death, and all kinds of complications are much higher. I’d rather control myeloma and get it to low volume before using these immunotherapy treatments. This is why

Remains the most important template for patients and hematologist/oncologists as a critical reference.

Thank you very much Florida Society of Clinical Oncology (FLASCO) for inviting me to give a talk on “clinical applications for MRD testing in multiple myeloma” at the FLASCO Fall Congress, October 23-25, 2025 in Orlando! #mmsm Multiple Myeloma RF International Myeloma Foundation Sylvester Comprehensive Cancer Center

HISTORIC AND PARADIGM CHANGING: FDA approves daratumumab for high risk smoldering multiple myeloma based on the AQUILA trial— the FIRST ever treatment approved for this indication. Excellent news and thanks to J&J Innovative Medicine and the huge worldwide team of investigators for

Working on first draft (sorry for typos and missing names, etc) -> Myeloma / Plasma Cell Dyscrasia ~ #ASH25Top10 (or so) #mmsm #mmMRD #ASH25 cc Surviving Myeloma – Taxiarchis Kourelis Rahul Banerjee, MD, FACP Daniel Auclair

Thank you again for your continued efforts to keep the myeloma community updated on the most highly regarded trials by myeloma specialists!

Surviving Myeloma For #ASCO26 #ASH26 I may "enforce" a top 10 only. :)

Myeloma / Plasma Cell Dyscrasia ~ #ASH25Top10 (or so) #mmsm #mmMRD #ASH25 - Mike Thompson, MD, PhD, FASCO - Update: 11/13/25 - cc Surviving Myeloma – Irene Ghobrial Taxiarchis Kourelis Rahul Banerjee, MD, FACP Daniel Auclair Murali Janakiram Joseph Mikhael Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰

Myeloma / Plasma Cell Dyscrasia ~ #ASH25Top10 (or so) #mmsm #mmMRD #ASH25 - Mike Thompson, MD, PhD, FASCO - Update: 11/19/25 - cc Surviving Myeloma – Irene Ghobrial Taxiarchis Kourelis Rahul Banerjee, MD, FACP Daniel Auclair Murali Janakiram Joseph Mikhael Luciano J Costa

Myeloma / Plasma Cell Dyscrasia ~ #ASH25Top10 (or so) #mmsm #mmMRD #ASH25 - Mike Thompson, MD, PhD, FASCO – DRAFT Update: 12/1/25 v2 - cc Surviving Myeloma – Irene Ghobrial Taxiarchis Kourelis Rahul Banerjee, MD, FACP Daniel Auclair Murali Janakiram Joseph Mikhael Luciano J Costa Ben Derman Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 C. Ola Landgren, M.D.

As always, an outstanding group of contributors! Helping the myeloma community with their knowledge and expertise!